{"id":"W3195243079","doi":"10.1182/blood.2020009984","title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":336,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; National Institute for Health and Care Research; Novartis Pharmaceuticals Corporation","keywords":"Bosutinib; Medicine; Open label; Randomized controlled trial; Internal medicine; Oncology; Imatinib; Nilotinib; Myeloid leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002858302,0.001852707,0.003032355,0.0004948673,0.0005174862,0.001330808,0.0009046187,0.001648251,0.004825438],"category_scores_gemma":[0.00227014,0.0007731278,0.002339632,0.0004295019,0.001291066,0.001292135,0.0004370833,0.00389642,0.0008762046],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001006078,"about_ca_system_score_gemma":0.001582945,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00101729,"about_ca_topic_score_gemma":0.003003028,"domain_scores_codex":[0.9990395,0.0005794595,0.00004386587,0.0001102503,0.00006354812,0.0001634076],"domain_scores_gemma":[0.9981078,0.0006845522,0.0004211333,0.0001140714,0.00008354132,0.0005890152],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9814715,0.009414114,0.0003226839,0.0001619221,0.0004299403,0.00002790774,0.00003159278,0.000247064,0.001778357,0.00006159794,0.0003562288,0.005696883],"study_design_scores_gemma":[0.8631331,0.1339746,0.001335976,0.00001750947,0.000274946,0.00002489464,0.00002063545,0.0004884404,0.0002931693,0.0001387033,0.000283835,0.00001428481],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992246,0.002129368,0.0003876894,0.0005123951,0.000454374,0.002588457,0.0005847878,0.00006949409,0.001027568],"genre_scores_gemma":[0.9900978,0.001608715,0.001076702,0.001128501,0.0005055831,0.00325401,0.000577565,0.00002048811,0.001730691],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004825438,"threshold_uncertainty_score":0.01614273,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0352400247850263,"score_gpt":0.3536891511236019,"score_spread":0.3184491263385756,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}